Stock VYGR VOYAGER THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Voyager Therapeutics, Inc.

Equities

VYGR

US92915B1061

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
8.53 USD +2.03% Intraday chart for Voyager Therapeutics, Inc. +14.96% +1.07%
Apr. 02 Voyager Therapeutics, Inc. Appoints Robin Swartz as Principal Accounting Officer CI
Apr. 02 Voyager Therapeutics, Inc. Announces CFO Changes CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
AQ
NORTHSTAR APPOINTS PETER PFREUNDSCHUH TO BOARD OF MANAGERS
AQ
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
AQ
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
AQ
Voyager Therapeutics: Q4 Earnings Snapshot
AQ
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
AQ
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
AQ
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
AQ
Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast
AQ
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research
AQ
Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference
AQ
Voyager Therapeutics Announces Pricing of Public Offering
AQ
Voyager Therapeutics Announces Proposed Public Offering
AQ
Voyager Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
AQ
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies
AQ
Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program
AQ
Voyager Therapeutics: Q3 Earnings Snapshot
AQ
Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VYGR Stock
  4. News Voyager Therapeutics, Inc.
  5. Press Releases